Seeking Alpha
04 Mar 2026, 23:03 UTC · 30w ago
Verdict
Headline takes no side. We score AMLX −0.20 across four claims — slightly bearish.
−0.20slightly bearish
More negative than 64% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
4 claims · scored −1 bearish … +1 bullish
Amylyx Pharmaceuticals discontinued the development of AMX0035 for Progressive Supranuclear Palsy (PSP).
More negative than 95% of claims this week
Amylyx was downgraded from 'Strong Buy' to 'Buy'.
Continue reading
5 related stories
More negative than 86% of claims this week
The company has a cash position of $317M, providing funding into 2028.
So whatStrong liquidity reduces the immediate risk of dilutive financing and ensures the company can reach its next major milestones.
More positive than 65% of claims this week
Topline data for avexitide in the phase 3 LUCIDITY trial is expected in Q3 2026.
More positive than 44% of claims this week
Which stocks this story touches
More negative than 64% of ticker scores this week
The company received a rating downgrade following the discontinuation of a drug candidate for PSP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
20h ago
+84.7%
Price is moving against the score
$27.79 vs $15.05 close before publication (Mar 4) · not market-adjusted
AMLX chart →
